Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Penumbra (PEN)
NYSE:PEN
Holding PEN?
Track your performance easily
Earnings Data
Report Date
Feb 25, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.9Last Year’s EPS
0.76Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 05, 2018
|% Change Since: 27.66%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Neutral
The earnings call reflected strong performance in the U.S. market, particularly in the thrombectomy business, and improving profitability metrics. However, international challenges, particularly in China and the European reimbursement landscape, tempered the overall outlook.Company Guidance
During Penumbra's Q3 2024 earnings call, guidance was provided with a total revenue forecast for the year ranging between $1.18 billion to $1.2 billion. The company raised the lower end of its U.S. thrombectomy growth projection to 24% to 25%, up from the previous 23% to 25%. Gross margin for the fourth quarter is expected to remain consistent with the third quarter's 66.5%, reflecting a 90 basis point improvement over the prior year, and non-GAAP operating margin is anticipated to expand sequentially. The adjusted EBITDA for Q3 2024 was reported at $56.7 million or 18.8% of total revenue. The company remains focused on executing a strategy that emphasizes innovation, clinical and economic data generation, investment in commercial and market access teams, and driving operating efficiencies to enhance profitability.Strong Overall Revenue Growth
Total revenue increased to $301 million, representing a year-over-year growth of 11.1% on a reported basis and 10.9% on a constant currency basis.
U.S. Thrombectomy Growth
U.S. thrombectomy business grew by 21.2% year-over-year to $162.1 million, with significant growth in the VTE franchise at 32% year-over-year.
Improving Profitability
Gross margins expanded to 66.5%, up 90 basis points over the prior year. Non-GAAP operating income increased to $40.3 million or 13.4% of revenue, up 110 basis points year-over-year.
New Product Approvals
Received FDA clearance for Lightning Bolt 6X and Lightning Bolt 12, enhancing the CAVT portfolio. CE Mark received for Lightning Flash 2.0 and Lightning Bolt 7, expanding European market presence.
Operating Cash Flow
Generated $51.3 million in operating cash, excluding the impact of a $100 million stock buyback.
---
PEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Oct 30, 2024 | $211.29 | $228.87 | +8.32% |
| Jul 30, 2024 | $173.09 | $167.09 | -3.47% |
| May 07, 2024 | $210.00 | $203.09 | -3.29% |
| Feb 22, 2024 | $262.68 | $238.37 | -9.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Penumbra (PEN) report earnings?
Penumbra (PEN) is schdueled to report earning on Feb 25, 2025, TBA Not Confirmed.
What is Penumbra (PEN) earnings time?
Penumbra (PEN) earnings time is at Feb 25, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PEN EPS forecast?
PEN EPS forecast for the fiscal quarter 2024 (Q4) is 0.9.
---